Stocks · News reference

Fortress Biotech Q2 EPS $(0.08) Beats $(0.20) Estimate, Sales $18.718M Beat $18.300M Estimate

Aug 13, 2026, 8:28 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncSep 8, 2026, 12:00 PMNa
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Fortress Biotech announced that CEO Lindsay A. Rosenwald will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will be available on-demand starting September 11, 2026, with one-on-one meetings scheduled for September 14-16, 2026. The company continues to advance its portfolio of marketed pharmaceutical products and development programs across oncology, dermatology, and rare diseases through partnerships with leading academic and biopharmaceutical institutions.
FBIO FBIOP
BenzingaJul 27, 2026, 12:03 PMBenzinga Newsdesk
Fortress Biotech’s Urica Therapeutics Says Crystalys Closes Oversubscribed $130M Series B Financing To Support Late-Stage Global Clinical Development And Commercialization Preparation For Dotinurad
Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics, Inc. ("Crystalys"), in
FBIO